Literature DB >> 28589894

Advising women with diabetes in pregnancy to express breastmilk in late pregnancy (Diabetes and Antenatal Milk Expressing [DAME]): a multicentre, unblinded, randomised controlled trial.

Della A Forster1, Anita M Moorhead2, Susan E Jacobs3, Peter G Davis4, Susan P Walker5, Kerri M McEgan6, Gillian F Opie5, Susan M Donath7, Lisa Gold8, Catharine McNamara6, Amanda Aylward9, Christine East10, Rachael Ford9, Lisa H Amir2.   

Abstract

BACKGROUND: Infants of women with diabetes in pregnancy are at increased risk of hypoglycaemia, admission to a neonatal intensive care unit (NICU), and not being exclusively breastfed. Many clinicians encourage women with diabetes in pregnancy to express and store breastmilk in late pregnancy, yet no evidence exists for this practice. We aimed to determine the safety and efficacy of antenatal expressing in women with diabetes in pregnancy.
METHODS: We did a multicentre, two-group, unblinded, randomised controlled trial in six hospitals in Victoria, Australia. We recruited women with pre-existing or gestational diabetes in a singleton pregnancy from 34 to 37 weeks' gestation and randomly assigned them (1:1) to either expressing breastmilk twice per day from 36 weeks' gestation (antenatal expressing) or standard care (usual midwifery and obstetric care, supplemented by support from a diabetes educator). Randomisation was done with a computerised random number generator in blocks of size two and four, and was stratified by site, parity, and diabetes type. Investigators were masked to block size but masking of caregivers was not possible. The primary outcome was the proportion of infants admitted to the NICU. We did the analyses by intention to treat; the data were obtained and analysed masked to group allocation. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000217909.
FINDINGS: Between June 6, 2011, and Oct 29, 2015, we recruited and randomly assigned 635 women: 319 to antenatal expressing and 316 to standard care. Three were not included in the primary analysis (one withdrawal from the standard care group, and one post-randomisation exclusion and one withdrawal from the antenatal expressing group). The proportion of infants admitted to the NICU did not differ between groups (46 [15%] of 317 assigned to antenatal expressing vs 44 [14%] of 315 assigned to standard care; adjusted relative risk 1·06, 95% CI 0·66 to 1·46). In the antenatal expressing group, the most common serious adverse event for infants was admission to the NICU for respiratory support (for three [<1%] of 317. In the standard care group, the most common serious adverse event for infants was moderate to severe encephalopathy with or without seizures (for three [<1%] of 315).
INTERPRETATION: There is no harm in advising women with diabetes in pregnancy at low risk of complications to express breastmilk from 36 weeks' gestation. FUNDING: Australian National Health and Medical Research Council.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28589894     DOI: 10.1016/S0140-6736(17)31373-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

1.  "It gave me so much confidence": First-time U.S. mothers' experiences with antenatal milk expression.

Authors:  Jill R Demirci; Melissa Glasser; Jessica Fichner; Erin Caplan; Katherine P Himes
Journal:  Matern Child Nutr       Date:  2019-05-23       Impact factor: 3.092

Review 2.  Strategies to improve neurodevelopmental outcomes in babies at risk of neonatal hypoglycaemia.

Authors:  Jane M Alsweiler; Deborah L Harris; Jane E Harding; Christopher J D McKinlay
Journal:  Lancet Child Adolesc Health       Date:  2021-04-06

3.  Oral dextrose gel to prevent hypoglycaemia in at-risk neonates.

Authors:  Taygen Edwards; Gordon Liu; Joanne E Hegarty; Caroline A Crowther; Jane Alsweiler; Jane E Harding
Journal:  Cochrane Database Syst Rev       Date:  2021-05-17

Review 4.  Maternal and newborn outcomes of antenatal breastmilk expression: a scoping review protocol.

Authors:  Imane Foudil-Bey; Malia Sq Murphy; Erin J Keely; Darine El-Chaâr
Journal:  BMJ Open       Date:  2020-05-12       Impact factor: 2.692

5.  Maternal pre-pregnancy overweight/obesity and gestational diabetes interaction on delayed breastfeeding initiation.

Authors:  Tanara Vogel Pinheiro; Marcelo Zubaran Goldani
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

6.  Perspectives and experiences of collecting antenatal colostrum in women who have had diabetes during pregnancy: a North Queensland semistructured interview study.

Authors:  Jordan Rita Rose Casey; Erin Louise Mogg; Jennifer Banks; Kathleen Braniff; Clare Heal
Journal:  BMJ Open       Date:  2019-01-03       Impact factor: 2.692

7.  Evaluating antenatal breastmilk expression outcomes: a scoping review.

Authors:  Imane Foudil-Bey; Malia S Q Murphy; Sandra Dunn; Erin J Keely; Darine El-Chaâr
Journal:  Int Breastfeed J       Date:  2021-03-12       Impact factor: 3.461

8.  Antenatal breastmilk expression for women with diabetes in pregnancy - a feasibility study.

Authors:  Maren Johnsen; Claus Klingenberg; Meta Brand; Arthur Revhaug; Gunnbjørg Andreassen
Journal:  Int Breastfeed J       Date:  2021-07-23       Impact factor: 3.461

9.  Delayed Lactogenesis II and potential utility of antenatal milk expression in women developing late-onset preeclampsia: a case series.

Authors:  Jill Demirci; Mandy Schmella; Melissa Glasser; Lisa Bodnar; Katherine P Himes
Journal:  BMC Pregnancy Childbirth       Date:  2018-03-15       Impact factor: 3.007

10.  Women's perspectives on antenatal breast expression: a cross-sectional survey.

Authors:  Frankie J Fair; Helen Watson; Rachel Gardner; Hora Soltani
Journal:  Reprod Health       Date:  2018-04-04       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.